Related Experiment Video
Updated: Jun 16, 2026
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
A randomized intervention of montelukast for post-bronchiolitis: effect on eosinophil degranulation
Chang-Keun Kim1, Jungi Choi, Hyo Bin Kim
1Department of Pediatrics and Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea.
The Journal of Pediatrics
|February 23, 2010
Summary
Montelukast significantly reduced eosinophil degranulation and recurrent wheezing in infants after respiratory syncytial virus (RSV) bronchiolitis. This finding suggests montelukast as a potential treatment for post-RSV wheezing.
Area of Science:
- Pediatric Pulmonology
- Allergy and Immunology
- Pharmacology
Background:
- Respiratory syncytial virus (RSV) bronchiolitis is a common cause of infant hospitalization.
- Post-bronchiolitis wheezing and eosinophil degranulation are significant clinical concerns.
- Limited therapeutic options exist for managing recurrent wheezing after RSV infection.
Purpose of the Study:
- To evaluate the efficacy of montelukast in reducing eosinophil degranulation.
- To assess the impact of montelukast on recurrent wheezing episodes following RSV bronchiolitis.
- To investigate montelukast's role in managing airway inflammation in infants post-RSV.
Main Methods:
- A double-blind, placebo-controlled trial involving 200 infants hospitalized with their first RSV bronchiolitis episode.
- Participants received either 4-mg montelukast granules or placebo for 3 months.
- Serum eosinophil-derived neurotoxin (EDN) levels and recurrent wheezing episodes were monitored for 12 months.
Main Results:
- Montelukast treatment significantly decreased serum EDN levels compared to placebo.
- A significant reduction in cumulative recurrent wheezing episodes was observed in the montelukast group at 12 months.
- EDN levels remained significantly different between groups throughout the 12-month follow-up.
Conclusions:
- Montelukast effectively reduces eosinophil degranulation in infants post-RSV bronchiolitis.
- Montelukast treatment is associated with a significant decrease in recurrent wheezing episodes.
- These findings support montelukast as a therapeutic option for managing post-RSV bronchiolitis complications.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: